HIV Infections
Conditions
Keywords
HIV Protease Inhibitors, Ritonavir, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load, ABT 378, efavirenz
Brief summary
The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).
Detailed description
All patients take ABT-378/ritonavir and efavirenz; there are no placebos in this study. Patients take study medications for 48 weeks, during which time there will be 15 study visits. There is a possibility of a study extension after 48 weeks.
Interventions
DRUGLopinavir/Ritonavir
DRUGEfavirenz
Sponsors
ViRx
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
0 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients may be eligible for this study if they: * Are HIV-positive. * Have a viral load (level of HIV in the blood) of at least 1,000 copies/ml. * Have been receiving stable (no changes) anti-HIV treatment that includes at least 1 PI for at least 8 weeks prior to study entry. * Have received more than 1 PI for at least 12 weeks each at some time in the past.
Exclusion criteria
Patients will not be eligible for this study if they: * Have had any active opportunistic (AIDS-related) infections within the past 30 days. * Have ever received nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as delavirdine, nevirapine, or efavirenz. * Have received certain medications. * Are pregnant or breast-feeding. * Abuse alcohol or drugs.
Countries
United States
Outcome results
None listed